Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. (Q39650689)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 June 2016

Language	Label	Description	Also known as
English	Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.	scientific article published on 27 June 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Giorgio Scagliotti

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

author name string

Jin Hyoung Kang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

David Smith

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Richard Rosenberg

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Keunchil Park

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Sang-We Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Thomas E Boyd

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Donald A Richards

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Silvia Novello

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Scott M Hynes

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Scott P Myrand

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Ji Lin

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Emily Nash Smyth

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Sameera Wijayawardana

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Aimee Bence Lin

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Mary Pinder-Schenck

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

27 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

625-635

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Management of non-small-cell lung cancer: recent developments

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

p53 down-regulates CHK1 through p21 and the retinoblastoma protein

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Comprehensive molecular profiling of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

New insights into checkpoint kinase 1 in the DNA damage response signaling network

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

The p53 network in lung carcinogenesis.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Prognostic role of p53 in stage III non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/27350064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/27350064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-016-0368-1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39650689&oldid=2203056809"